No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients

No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients

Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking.Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients.Methods: The plasma proteom...

Full description

Bibliographic Details
Main Authors: Claire Bridel, Anand J. C. Eijlers, Wessel N. van Wieringen, Marleen Koel-Simmelink, Cyra E. Leurs, Menno M. Schoonheim, Joep Killestein, Charlotte E. Teunissen
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-10-01
Series:Frontiers in Molecular Neuroscience
Subjects:
multiple sclerosis
prognosis
proteomics
MRI
cognition
Online Access:https://www.frontiersin.org/article/10.3389/fnmol.2018.00371/full
Description
Summary:Background: The clinical course of relapsing-remitting multiple sclerosis (RRMS) is highly heterogeneous and prognostic biomarkers at time of diagnosis are lacking.Objective: We investigated the predictive value of the plasma proteome at time of diagnosis in RRMS patients.Methods: The plasma proteome was interrogated using a novel aptamer-based proteomics platform, which allows to measure the levels of a predefined set of 1310 proteins.Results: In 67 clinically and radiologically well characterized RRMS patients, we found no association between the plasma proteome at diagnosis and clinical, cognitive or MRI outcomes after 11 years.Conclusions: Proteomics studies on cerebrospinal fluid may be better suited to identify prognostic biomarkers in early RRMS.
ISSN:1662-5099

Similar Items